Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
12 participants
OBSERVATIONAL
2011-08-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interdialytic Peritoneal UltraFiltration in HemoDialysis Patients
NCT04603014
Comparison of Conventional Dialysis and the Allient System
NCT00788905
Clotting With Different Dialyzer Membranes
NCT02546037
Assessment of a Wearable Ultrafiltration Device
NCT06832696
Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis
NCT01892839
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will compare the degree of blood cleansing achieved with the new 2008 Sorbent System using two different speeds at which the dialysate runs through the dialysis machine. This will tell us if the faster speed really does provide better cleaning (and how much) with this new machine.
How well the blood of a patient is cleaned by this procedure is determined by several factors. For example, longer treatment times generally provide better blood cleansing. Higher speeds at which the cleaning fluid runs through the artificial kidney do, too.
Since the 2008 Sorbent System is a new machine (and in some ways different from standard hemodialysis machines), other aspects may be different, too, between the 2008 Sorbent System and regular hemodialysis machines. Specifically, this study looks at how well this new machine corrects the patients' acid-base status (a common requirement in these patients), what effect the treatment has on inflammation in the patients' blood, how the levels of important substances in the blood are influenced (acetate, sulfate, nitrate, carbon dioxide), and if cleaning fluid in the 2008 Sorbent System contains any substances that are not found in the cleaning fluid used by regular hemodialysis machines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2008 Sorbent system
Hemodialysis with the 2008 Sorbent system
2008 Sorbent System
2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2008 Sorbent System
2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* end-stage renal disease (ESRD) patient on chronic high-flux hemodialysis for \</= 6 months at time of enrollment
* well-functioning fistula, graft or catheter as hemodialysis access, achieving blood flow rates of \>/= 300 mL/min
* ability to understand the English language
Exclusion Criteria
* Severe Coronary Heart Disease or Heart Failure (New York Heart Association class IV)
* Active Infections
* Hepatitis B
* Any other active infection that has required antibiotic treatment in the preceding eight weeks
* Pre-study lab values of any of the following (in the most recent routine lab work)
* Sodium - Na+ \> 150 mmol/L, Na+ \< 132 mmol/L
* Potassium - K+ \> 6.5 mmol/L, K+ \< 3.5 mmol/L
* Total Calcium - Ca \> 12 mg/dL (3 mmol/L), total Ca \< 7.2 mg/dL (1.8 mmol/L)
18 Years
88 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Renal Solutions, Inc.
INDUSTRY
Renal Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Kotanko, MD
Role: PRINCIPAL_INVESTIGATOR
Renal Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yorkville Dialysis Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
150-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.